JP Morgan Healthcare Conference, Day 3: Grail, Ultima Genomics, Seer, GeneDx, Quanterix
Highlights from the third day included Quanterix's announcement of a new protein detection platform, to be launched later this year.
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
Biden Cancer Moonshot Announces New Initiatives to Improve Diagnosis, Precision Treatments
The program announced a series of new public and private initiatives and projects designed to support its stated goal of halving the cancer death rate over the next 25 years.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
Clinical customers helped Illumina place 91 NovaSeq X instruments in the fourth quarter. CFO Ankur Dhingra said many planned to use them for MRD testing.
Truveta Genome Project Launches With $320M Investment From Regeneron, Illumina, Health Systems
The initiative aims to use genetic data from tens of millions of volunteers to create the largest and most diverse database of genotypic and phenotypic information.